Literature DB >> 20104517

Comparison of natural histories of human papillomavirus detected by clinician- and self-sampling.

Anna-Barbara Moscicki1, Lea Widdice, Yifei Ma, Sepideh Farhat, Susanna Miller-Benningfield, Janet Jonte, Julie Jay, Cheryl Godwin de Medina, Evelyn Hanson, Lisa Clayton, Stephen Shiboski.   

Abstract

New strategies for cervical cancer screening include human papillomavirus (HPV) DNA testing. Using self-testing methods would increase access to testing in both developed and developing countries. The purpose of this study was to compare time-to-clearance of specific HPV types between clinician-collected-lavage (CC-L) and self-collected (SC) sampling in a single cohort. CC-L and SC samples were obtained every 4 months at alternate 2-month windows from 537 women. Eighteen high-risk (HR) HPV and 4 low-risk (LR) HPV were examined. Proportional hazards model was used to compare time-to-clearance between methods for combined HR and for 13 specific HPV types. Prentice-Wilcoxon test was used for within-subject paired comparison. In the independent analysis for combined HR and LR types, no differences were found. For specific types, time-to-clearance for all HPV types examined between CC-L and SC samples was similar except for HPV 66 which showed a trend to clear slower by SC (p = 0.09). When comparing methods in the same woman, time-to-clearance was similar for all types except for HPV 16 which showed a trend to clear slower by CC-L means (p = 0.08). When we examined pattern of clearance among the CC-L samples, the fastest types to clear were HPV 6, 18, 66, 84 and 39 and the slowest were HPV 62, 68, 59 and 16. These patterns of fast and slow were similar for SC samples. Our findings suggest using SC vaginal swabs would observe similar natural histories of HPV compared to studies using CC-L specimens making self-testing feasible for repeated HPV DNA detection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20104517      PMCID: PMC3132413          DOI: 10.1002/ijc.25199

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  30 in total

1.  Regression of low-grade squamous intra-epithelial lesions in young women.

Authors:  Anna-Barbara Moscicki; Stephen Shiboski; Nancy K Hills; Kimberly J Powell; Naomi Jay; Evelyn N Hanson; Susanna Miller; K Lisa Canjura-Clayton; Sepidah Farhat; Jeanette M Broering; Teresa M Darragh
Journal:  Lancet       Date:  2004 Nov 6-12       Impact factor: 79.321

2.  Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females.

Authors:  A B Moscicki; N Hills; S Shiboski; K Powell; N Jay; E Hanson; S Miller; L Clayton; S Farhat; J Broering; T Darragh; J Palefsky
Journal:  JAMA       Date:  2001-06-20       Impact factor: 56.272

3.  Primary screening for cervical cancer through self sampling.

Authors:  F Holanda; A Castelo; T M C W Veras; F M L de Almeida; M Z Lins; G B Dores
Journal:  Int J Gynaecol Obstet       Date:  2006-09-25       Impact factor: 3.561

4.  Development and duration of human papillomavirus lesions, after initial infection.

Authors:  Rachel L Winer; Nancy B Kiviat; James P Hughes; Diane E Adam; Shu-Kuang Lee; Jane M Kuypers; Laura A Koutsky
Journal:  J Infect Dis       Date:  2005-01-21       Impact factor: 5.226

5.  A population-based study of squamous cell vaginal cancer: HPV and cofactors.

Authors:  Janet R Daling; Margaret M Madeleine; Stephen M Schwartz; Katherine A Shera; Joseph J Carter; Barbara McKnight; Peggy L Porter; Denise A Galloway; James K McDougall; Hisham Tamimi
Journal:  Gynecol Oncol       Date:  2002-02       Impact factor: 5.482

6.  Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results.

Authors:  Nubia Muñoz; Fabián Méndez; Héctor Posso; Mónica Molano; Adrian J C van den Brule; Margarita Ronderos; Chris Meijer; Alvaro Muñoz
Journal:  J Infect Dis       Date:  2004-11-22       Impact factor: 5.226

7.  Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination.

Authors:  Helen Trottier; Salaheddin Mahmud; José Carlos M Prado; Joao S Sobrinho; Maria C Costa; Thomas E Rohan; Luisa L Villa; Eduardo L Franco
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

8.  The natural history of type-specific human papillomavirus infections in female university students.

Authors:  Harriet Richardson; Gail Kelsall; Pierre Tellier; Hélène Voyer; Michal Abrahamowicz; Alex Ferenczy; François Coutlée; Eduardo L Franco
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-06       Impact factor: 4.254

9.  High prevalence of oncogenic human papilloma virus in women not attending organized cytological screening.

Authors:  Harriet Stenvall; Ingrid Wikström; Erik Wilander
Journal:  Acta Derm Venereol       Date:  2007       Impact factor: 4.437

10.  Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study.

Authors:  Marc T Goodman; Yurii B Shvetsov; Katharine McDuffie; Lynne R Wilkens; Xuemei Zhu; Pamela J Thompson; Lily Ning; Jeffrey Killeen; Lori Kamemoto; Brenda Y Hernandez
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

View more
  20 in total

1.  Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women.

Authors:  Anna-Barbara Moscicki; Yifei Ma; Charles Wibbelsman; Teresa M Darragh; Adaleen Powers; Sepideh Farhat; Stephen Shiboski
Journal:  Obstet Gynecol       Date:  2010-12       Impact factor: 7.661

Review 2.  Acceptability, Feasibility and Uptake of HPV Self-Sampling Among Immigrant Minority Women: a Focused Literature Review.

Authors:  Sarah Marshall; Mandana Vahabi; Aisha Lofters
Journal:  J Immigr Minor Health       Date:  2019-12

3.  Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention.

Authors:  Seoyoung C Kim; Sarah Feldman; Anna-Barbara Moscicki
Journal:  Rheumatology (Oxford)       Date:  2018-07-01       Impact factor: 7.580

Review 4.  Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy.

Authors:  Patti E Gravitt; Jerome L Belinson; Jorge Salmeron; Keerti V Shah
Journal:  Int J Cancer       Date:  2011-08-01       Impact factor: 7.396

5.  Development of a novel liquid bead array human papillomavirus genotyping assay (PGMY-LX) and comparison with linear array for continuity in longitudinal cohort studies.

Authors:  Sepideh Farhat; Mark E Scott; Yifei Ma; Anna-Barbara Moscicki
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

6.  Active squamous metaplasia of the cervical epithelium is associated with subsequent acquisition of human papillomavirus 16 infection among healthy young women.

Authors:  Loris Y Hwang; Yifei Ma; Stephen C Shiboski; Sepideh Farhat; Janet Jonte; Anna-Barbara Moscicki
Journal:  J Infect Dis       Date:  2012-06-13       Impact factor: 5.226

7.  Population-based type-specific prevalence of high-risk human papillomavirus infection in Estonia.

Authors:  Anneli Uusküla; Mart Kals; Liina Kosenkranius; Louise-Anne McNutt; Jack DeHovitz J
Journal:  BMC Infect Dis       Date:  2010-03-11       Impact factor: 3.090

8.  Natural history of anal human papillomavirus infection in heterosexual women and risks associated with persistence.

Authors:  Anna-Barbara Moscicki; Yifei Ma; Sepideh Farhat; Julie Jay; Evelyn Hanson; Susanna Benningfield; Janet Jonte; Cheryl Godwin-Medina; Robert Wilson; Stephen Shiboski
Journal:  Clin Infect Dis       Date:  2013-12-23       Impact factor: 9.079

9.  Human Papillomavirus (HPV) Infections and the Importance of HPV Vaccination.

Authors:  Chia-Ching J Wang; Joel M Palefsky
Journal:  Curr Epidemiol Rep       Date:  2015-03-26

Review 10.  Updating the natural history of human papillomavirus and anogenital cancers.

Authors:  Anna-Barbara Moscicki; Mark Schiffman; Ann Burchell; Ginesa Albero; Anna R Giuliano; Marc T Goodman; Susanne K Kjaer; Joel Palefsky
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.